A large randomized Phase III NRG-GU005 trial compared stereotactic body radiation therapy (SBRT) with moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in localized prostate cancer. Results reported favorable bowel-related quality-of-life outcomes for SBRT, targeting symptom burden differences rather than efficacy endpoints in this summary. SBRT has been gaining adoption as more clinics consider highly focused radiation schedules, and the trial’s quality-of-life findings address the trade-off clinicians often weigh when selecting fractionation intensity and planning complexity. The update provides more granular patient-centered evidence for radiotherapy decision-making in a common malignancy.